病毒学治愈丙型肝炎人群肝癌监测的发病率阈值
该研究用马尔可夫微观模拟模型估算病毒学治愈丙型肝炎合并肝硬化或进展期纤维化患者中,每100人年肝癌发病率超过0.7(支付意愿10万美元/质量调整生命年)或0.4(支付意愿15万美元/质量调整生命年)时,每半年超声联合甲胎蛋白监测具有成本效果,阈值低于指南既往采用的1.5/100人年。
要点
- 病毒学治愈丙肝合并肝硬化或进展期纤维化者,肝癌监测成本效果阈值低于既往1.5/100人年。
- 支付意愿10万美元/质量调整生命年时,阈值0.7/100人年;15万美元时阈值0.4/100人年。
- 阈值0.7/100人年时,每10万肝硬化者监测较不监测增加2650生命年,进展期纤维化者增加5700生命年。
核心结论
- 当前肝癌发病率阈值远低于既往用于指导监测决策的1.5%发病率值,更新临床指南可改善肝癌早期诊断。
研究设计与样本
- 研究构建口服直接抗病毒药物实现病毒学治愈的丙型肝炎患者肝癌自然史的马尔可夫微观模拟模型,使用已发表的丙肝自然史、病毒学治愈后竞争风险、肝癌肿瘤进展、真实世界肝癌监测依从性、当代肝癌治疗选择及相关成本和不同健康状态效用数据,估算每半年超声联合甲胎蛋白监测具有成本效果的肝癌发病率阈值。
主要发现
- 病毒学治愈丙型肝炎合并肝硬化或进展期纤维化者,肝癌发病率超过0.7/100人年时每半年监测具有成本效果(支付意愿10万美元/质量调整生命年)。
- 肝癌发病率0.7/100人年时,与不监测相比,每10万肝硬化者监测增加2650生命年,每10万进展期纤维化者增加5700生命年。
- 支付意愿15万美元/质量调整生命年时,肝癌发病率超过0.4/100人年监测即具有成本效果。
- 敏感性分析显示阈值大多仍低于1.5/100人年。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Guidelines recommend biannual surveillance for hepatocellular carcinoma (HCC) in hepatitis C individuals with cirrhosis if the HCC incidence rate is above 1.5 per 100 person-years (PY). However, the incidence threshold for surveillance in individuals who achieve a virologic cure is unknown. We estimated the HCC incidence rate above which routine HCC surveillance is cost-effective in this growing population of virologically cured hepatitis C individuals with cirrhosis or advanced fibrosis. METHODS: We developed a Markov-based microsimulation model of the natural history of HCC in individuals with hepatitis C who achieved virologic cure with oral direct-acting antivirals. We used published data on the natural history of hepatitis C, competing risk post virologic cure, HCC tumor progression, real-world HCC surveillance adherence, contemporary HCC treatment options and associated costs, and utilities of different health states. We estimated the HCC incidence above which biannual HCC surveillance using ultrasound and alpha-fetoprotein would be cost-effective. RESULTS: In virologically cured hepatitis C individuals with cirrhosis or advanced fibrosis, HCC surveillance is cost-effective if HCC incidence exceeds 0.7 per 100 PY using $100,000 per quality-adjusted life year willingness-to-pay. At this HCC incidence, routine HCC surveillance would result in 2650 and 5700 additional life years per 100,000 cirrhosis and advanced fibrosis persons, respectively, compared with no surveillance. At $150,000 willingness-to-pay, surveillance is cost-effective if HCC incidence exceeds 0.4 per 100 PY. Sensitivity analysis showed that the threshold mostly remained below 1.5 per 100 PY. CONCLUSIONS: The contemporary HCC incidence threshold is much lower than the previous 1.5% incidence value used to guide HCC surveillance decisions. Updating clinical guidelines could improve the early diagnosis of HCC.
引用
- Chhatwal J, Hajjar A, Mueller PP, et al. Hepatocellular Carcinoma Incidence Threshold for Surveillance in Virologically Cured Hepatitis C Individuals. Clin Gastroenterol Hepatol. 2023. PMID: 37302445. doi:10.1016/j.cgh.2023.05.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。